Display options
Cite
Casey SC, Li Y, Fan AC, et al. Oncogene withdrawal engages the immune system to induce sustained cancer regression. J Immunother Cancer. 2014;2:24doi: 10.1186/2051-1426-2-24.
Casey, S. C., Li, Y., Fan, A. C., & Felsher, D. W. (2014). Oncogene withdrawal engages the immune system to induce sustained cancer regression. Journal for immunotherapy of cancer, 224. https://doi.org/10.1186/2051-1426-2-24
Casey, Stephanie C, et al. "Oncogene withdrawal engages the immune system to induce sustained cancer regression." Journal for immunotherapy of cancer vol. 2 (2014): 24. doi: https://doi.org/10.1186/2051-1426-2-24
Casey SC, Li Y, Fan AC, Felsher DW. Oncogene withdrawal engages the immune system to induce sustained cancer regression. J Immunother Cancer. 2014 Jul 15;2:24. doi: 10.1186/2051-1426-2-24. eCollection 2014. PMID: 25089198; PMCID: PMC4118610.
Copy Download .nbib Format: NLM
Share it on

J Immunother Cancer. 2014 Jul 15;2:24. doi: 10.1186/2051-1426-2-24. eCollection 2014.

Oncogene withdrawal engages the immune system to induce sustained cancer regression.

Journal for immunotherapy of cancer

Stephanie C Casey, Yulin Li, Alice C Fan, Dean W Felsher

Affiliations

  1. Division of Oncology, Departments of Medicine and Pathology, Stanford University School of Medicine, 269 Campus Drive, CCSR 1105, Stanford 94305-5151, CA, USA.

PMID: 25089198 PMCID: PMC4118610 DOI: 10.1186/2051-1426-2-24

Abstract

The targeted inactivation of a single oncogene can induce dramatic tumor regression, suggesting that cancers are "oncogene addicted." Tumor regression following oncogene inactivation has been thought to be a consequence of restoration of normal physiological programs that induce proliferative arrest, apoptosis, differentiation, and cellular senescence. However, recent observations illustrate that oncogene addiction is highly dependent upon the host immune cells. In particular, CD4(+) helper T cells were shown to be essential to the mechanism by which MYC or BCR-ABL inactivation elicits "oncogene withdrawal." Hence, immune mediators contribute in multiple ways to the pathogenesis, prevention, and treatment of cancer, including mechanisms of tumor initiation, progression, and surveillance, but also oncogene inactivation-mediated tumor regression. Data from both the bench and the bedside illustrates that the inactivation of a driver oncogene can induce activation of the immune system that appears to be essential for sustained tumor regression.

Keywords: MYC; Oncogene addiction; Tumor immunology; Tumor microenvironment

References

  1. Curr Opin Immunol. 2013 Apr;25(2):246-58 - PubMed
  2. Cancer Cell. 2011 Dec 13;20(6):755-67 - PubMed
  3. Ann N Y Acad Sci. 2012 Oct;1271:1-9 - PubMed
  4. Cold Spring Harb Perspect Med. 2012 May;2(5):a006627 - PubMed
  5. Oncoimmunology. 2013 Aug 1;2(8):e25961 - PubMed
  6. Nat Med. 2007 Jan;13(1):54-61 - PubMed
  7. Int J Oncol. 2007 Nov;31(5):1133-9 - PubMed
  8. Curr Med Chem. 2011;18(34):5174-84 - PubMed
  9. Adv Pharmacol. 2012;65:335-59 - PubMed
  10. Cancer Cell. 2004 Dec;6(6):577-86 - PubMed
  11. Cancer Immun. 2003 Feb 14;3:2 - PubMed
  12. Cell. 2011 Sep 16;146(6):904-17 - PubMed
  13. Immunol Rev. 2008 Aug;224:141-65 - PubMed
  14. Nat Rev Cancer. 2012 Mar 22;12(4):237-51 - PubMed
  15. Science. 2002 Jul 5;297(5578):63-4 - PubMed
  16. Science. 2002 Jul 5;297(5578):102-4 - PubMed
  17. Curr Oncol Rep. 2012 Jun;14(3):230-9 - PubMed
  18. Blood. 2012 Sep 13;120(11):2229-39 - PubMed
  19. Cancer Res. 2008 May 1;68(9):3081-6; discussion 3086 - PubMed
  20. Br J Pharmacol. 2012 Jan;165(2):328-44 - PubMed
  21. Clin Cancer Res. 2011 Oct 15;17(20):6574-81 - PubMed
  22. Blood. 2012 Jun 7;119(23):5343-4 - PubMed
  23. J Immunol. 2001 Feb 15;166(4):2276-82 - PubMed
  24. Cell. 2011 Mar 4;144(5):646-74 - PubMed
  25. Cell Death Differ. 2014 Jan;21(1):79-91 - PubMed
  26. Curr Opin Cell Biol. 2003 Oct;15(5):640-4 - PubMed
  27. Cancer J. 2011 Sep-Oct;17(5):351-8 - PubMed
  28. J Acquir Immune Defic Syndr. 2003 Apr 15;32(5):527-33 - PubMed
  29. Clin Cancer Res. 2012 Mar 1;18(5):1386-94 - PubMed
  30. Clin Cancer Res. 2012 Aug 1;18(15):4173-82 - PubMed
  31. Front Oncol. 2011 Mar 28;1:1 - PubMed
  32. Leukemia. 2013 Sep;27(9):1920-3 - PubMed
  33. Clin Oncol (R Coll Radiol). 2008 Mar;20(2):101-12 - PubMed
  34. Blood. 2010 Aug 5;116(5):679-86 - PubMed
  35. Target Oncol. 2013 Mar;8(1):55-67 - PubMed
  36. Cancer Res. 1992 Oct 1;52(19 Suppl):5477s-5478s - PubMed
  37. Cancer Res. 2009 Jul 1;69(13):5383-91 - PubMed
  38. Nature. 1999 Jul 29;400(6743):468-72 - PubMed
  39. Semin Immunol. 2010 Jun;22(3):113-24 - PubMed
  40. Blood. 1997 Sep 15;90(6):2188-95 - PubMed
  41. J Clin Invest. 2013 Mar;123(3):1371-81 - PubMed
  42. Clin Cancer Res. 2008 Oct 15;14(20):6674-82 - PubMed
  43. Clin Lymphoma Myeloma. 2007 Mar;7 Suppl 2:S64-70 - PubMed
  44. Oncoimmunology. 2013 Mar 1;2(3):e23510 - PubMed
  45. J Immunother. 2010 Jan;33(1):1-7 - PubMed
  46. Cell. 2000 Oct 27;103(3):481-90 - PubMed
  47. Oncoimmunology. 2012 Sep 1;1(6):997-999 - PubMed
  48. Cancer Discov. 2011 Dec;1(7):562-72 - PubMed
  49. J Immunol. 2011 Mar 15;186(6):3401-9 - PubMed
  50. Cold Spring Harb Perspect Biol. 2012 Dec 01;4(12): - PubMed
  51. Nat Immunol. 2012 Dec;13(12):1129-32 - PubMed
  52. J Natl Cancer Inst. 2011 Aug 17;103(16):1222-6 - PubMed
  53. Clin Pharmacol. 2013 Aug 09;5(Suppl 1):21-7 - PubMed
  54. Mt Sinai J Med. 2010 Nov-Dec;77(6):573-86 - PubMed
  55. Cancer Cell. 2010 Nov 16;18(5):403-5 - PubMed
  56. Cancer Cell. 2010 Mar 16;17(3):262-72 - PubMed
  57. Nucleic Acids Res. 2000 Jun 1;28(11):2268-75 - PubMed
  58. Curr Stem Cell Res Ther. 2010 Dec;5(4):372-8 - PubMed
  59. Oncogene. 2000 May 25;19(23):2780-5 - PubMed
  60. Cancer Res. 2010 Jul 1;70(13):5213-9 - PubMed
  61. Clin Dev Immunol. 2012;2012:890178 - PubMed
  62. PLoS One. 2011 Apr 18;6(4):e18925 - PubMed
  63. Cell. 2008 Jun 13;133(6):1019-31 - PubMed
  64. Semin Cancer Biol. 2006 Oct;16(5):344-7 - PubMed
  65. Nat Rev Cancer. 2007 Feb;7(2):139-47 - PubMed
  66. Arch Pathol Lab Med. 2013 Jun;137(6):828-60 - PubMed
  67. Biol Direct. 2012 Sep 25;7:31 - PubMed
  68. Cell. 2008 Jun 13;133(6):1006-18 - PubMed
  69. Genes Dev. 2002 Oct 1;16(19):2530-43 - PubMed
  70. Cancer Res. 2006 Jan 15;66(2):999-1006 - PubMed
  71. J Immunol. 2012 Sep 15;189(6):3209-20 - PubMed
  72. Nature. 2004 Oct 28;431(7012):1112-7 - PubMed
  73. Proc Natl Acad Sci U S A. 2006 Oct 31;103(44):16266-71 - PubMed
  74. J Exp Med. 2006 Jul 10;203(7):1651-6 - PubMed
  75. Genes Dev. 2007 Dec 15;21(24):3214-31 - PubMed
  76. Ann Oncol. 2011 Aug;22(8):1703-16 - PubMed
  77. Nat Rev Drug Discov. 2012 Nov;11(11):873-86 - PubMed
  78. Cancer Treat Res. 2000;103:57-75 - PubMed
  79. Pigment Cell Melanoma Res. 2012 May;25(3):297-8 - PubMed
  80. Clin Cancer Res. 2013 Jan 15;19(2):393-403 - PubMed
  81. Nat Rev Cancer. 2002 May;2(5):373-82 - PubMed
  82. Nat Genet. 2000 Jan;24(1):57-60 - PubMed
  83. Br J Haematol. 2012 Apr;157(2):254-6 - PubMed
  84. Eur J Cancer. 2010 Jul;46(11):2010-9 - PubMed
  85. Nature. 2011 Dec 21;480(7378):480-9 - PubMed
  86. Nat Rev Cancer. 2005 Sep;5(9):689-98 - PubMed
  87. Nat Rev Cancer. 2003 May;3(5):375-80 - PubMed
  88. Nat Med. 2007 Oct;13(10):1211-8 - PubMed
  89. J Clin Invest. 2012 Mar;122(3):1066-75 - PubMed
  90. J Clin Oncol. 2012 Nov 20;30(33):4161-7 - PubMed
  91. AIDS. 2007 Jan 11;21(2):207-13 - PubMed
  92. Eur J Cancer. 2011 Mar;47(5):690-6 - PubMed
  93. Lancet Oncol. 2014 Jan;15(1):69-77 - PubMed
  94. Nat Rev Clin Oncol. 2011 Jan;8(1):25-37 - PubMed
  95. N Engl J Med. 2007 May 31;356(22):2271-81 - PubMed
  96. Expert Rev Anticancer Ther. 2013 Jan;13(1):29-42 - PubMed
  97. Nat Med. 2007 Jan;13(1):84-8 - PubMed
  98. Clin Cancer Res. 2012 Mar 1;18(5):1192-4 - PubMed
  99. Blood. 2012 Oct 4;120(14):2843-52 - PubMed
  100. Mol Cell. 1999 Aug;4(2):199-207 - PubMed
  101. Blood. 2010 Aug 5;116(5):772-82 - PubMed
  102. Proc Natl Acad Sci U S A. 2010 Oct 26;107(43):18545-50 - PubMed
  103. Nat Rev Cancer. 2001 Oct;1(1):46-54 - PubMed
  104. Nature. 2013 Nov 28;503(7477):548-51 - PubMed
  105. Anticancer Res. 2014 Apr;34(4):1493-505 - PubMed
  106. Carcinogenesis. 2011 May;32(5):650-8 - PubMed
  107. Annu Rev Immunol. 2009;27:83-117 - PubMed
  108. Cancer Cell. 2008 Jun;13(6):507-18 - PubMed
  109. Nat Rev Immunol. 2006 Oct;6(10):715-27 - PubMed
  110. Cancer Res. 2009 Apr 15;69(8):3563-9 - PubMed
  111. Ann Pharmacother. 2013 Feb;47(2):189-97 - PubMed
  112. J Clin Invest. 2013 Oct;123(10):4375-89 - PubMed
  113. Science. 2007 Nov 16;318(5853):1108-13 - PubMed
  114. Bull Cancer. 2005 Feb;92(2):E13-8 - PubMed
  115. Mayo Clin Proc. 2012 Oct;87(10):991-1003 - PubMed
  116. J Mammary Gland Biol Neoplasia. 2010 Dec;15(4):411-21 - PubMed
  117. Cell Mol Life Sci. 2012 Mar;69(6):931-4 - PubMed
  118. Blood. 2006 Nov 1;108(9):3112-20 - PubMed
  119. Cancer Cell. 2010 Nov 16;18(5):485-98 - PubMed

Publication Types

Grant support